Close Menu

NEW YORK – Aprea Therapeutics said on Wednesday that it will initiate a Phase I trial exploring the activity of APR-548 in TP53-mutant myelodysplastic syndromes (MDS).

APR-548 is a small molecule reactivator of mutant p53 that Boston-headquartered Aprea is developing for oral administration. Half of all tumors harbor mutations in TP53, making it one of the most common genetic aberrations involved in cancer, and cancer patients with TP53 mutations in their tumors often have poor overall survival and tend to develop resistance to available therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.